JRCT ID: jRCT2080225299
Registered date:03/08/2020
Basic Information
| Recruitment status | completed |
|---|---|
| Health condition(s) or Problem(s) studied | |
| Date of first enrollment | 25/07/2020 |
| Target sample size | 354 |
| Countries of recruitment | Japan,Asia except Japan,North America,Europe |
| Study type | Interventional |
| Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : Ravulizumab Therapeutic category code : 639 Other biological preparations Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : Placebo Therapeutic category code : 639 Other biological preparations Dosage and Administration for Investigational material : |
Outcome(s)
| Primary Outcome | efficacy |
|---|---|
| Secondary Outcome | safety efficacy pharmacokinetics pharmacodynamics |
Key inclusion & exclusion criteria
| Age minimum | >= 18age old |
|---|---|
| Age maximum | Not applicable |
| Gender | Both |
| Include criteria | |
| Exclude criteria |
Related Information
| Primary Sponsor | |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | |
| Secondary ID(s) | NCT04248465,JapicCTI-205395 |
Contact
| Public contact | |
| Name | |
| Address | |
| Telephone | +1-855-752-2356 |
| clinicaltrials@alexion.com | |
| Affiliation | |
| Scientific contact | |
| Name | |
| Address | |
| Telephone | +1-855-752-2356 |
| clinicaltrials@alexion.com | |
| Affiliation | |